Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

AbbVie : Recent Reports from Abbvie Inc. Highlight Findings in Thiazoles (In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:57pm CEST

Recent Reports from Abbvie Inc. Highlight Findings in Thiazoles (In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance)

By a News Reporter-Staff News Editor at Drug Week -- A new study on Thiazoles is now available. According to news reporting from North Chicago, Illinois, by NewsRx journalists, research stated, "Ritonavir (RTV) is a weakly basic drug with a pH-dependent solubility. In vitro dissolution and supersatuation behaviors of three Norvir oral products including the tablet, powder, and solution were investigated by two biorelevant dissolution methods with pH alteration: a two-stage dissolution test and a biphasic dissolution-partition test."

Financial support for this research came from AbbVie (see also Thiazoles).

The news correspondents obtained a quote from the research from Abbvie Inc., "The two-stage dissolution test revealed a high degree of supersaturation of RTV from these products accompanied by the occurrence of liquid-liquid phase separation (LLPS) in biorelevant dissolution media. Higher, stable apparent RTV concentrations were observed in the FeSSIF-V2 as compared to those in the FaSSIF-V2, which suggested a food effect with higher exposure in the fed state. This is inconsistent with the evaluation in vivo. The biphasic test revealed significantly lower degrees of supersaturation of RTV in the aqueous media from these dosage forms as compared to results of the two-stage dissolution test. RTV concentrations in octanol at 6 h obtained from the tablet and powder with the use of the biorelevant media are consistent with corresponding in vivo AUC and Cmax under the fasting and moderate fat fed (MFF) states and predict the food effect. The underlying mechanisms responsible for the food effect are also proposed. Fractional partition profiles of RTV obtained in octanol from these three Norvir oral products are in agreement with the corresponding fractional absorption profiles in vivo under both the fasting and MFF states."

According to the news reporters, the research concluded: "This study reveals a complex interplay among the dissolution, precipitation, and partition processes from these formulations that dictate the oral exposure of RTV."

For more information on this research see: In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance. Molecular Pharmaceutics, 2017;():. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)

Our news journalists report that additional information may be obtained by contacting H. Xu, NCE-Formulation Sciences, Drug Product Development and Clinical Pharmacology and Pharmacometrics, Abbvie Inc , 1 North Waukegan Road, North Chicago, Illinois 60064, United States. Additional authors for this research include S. Vela, Y. Shi, P. Marroum and P. Gao.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1021/acs.molpharmaceut.7b00552. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Antiinfectives, Antiretrovirals, Antivirals, Illinois, Ritonavir, Thiazoles, North Chicago, United States, Drugs and Therapies, Protease Inhibitors, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
08:15pABBVIE INVESTIGATION : Bernstein Liebhard LLP Announces Investigation Of AbbVie ..
PR
12:29pABBVIE : California Sues AbbVie Alleging Kickbacks For Humira
AQ
11:07aEU approves fifth copy of AbbVie's $18 billion drug Humira
RE
10:08aUNITY BIOTECHNOLOGY : Mayo Clinic team implicates senescent cells in neurodegene..
AQ
09/19ABBVIE : Thinking about buying stock in AbbVie, Cronos Group, E-Trade, Netflix o..
PR
09/19ABBVIE : to Host Third-Quarter 2018 Earnings Conference Call
AQ
09/18ABBVIE INC. : Entry into a Material Definitive Agreement, Termination of a Mater..
AQ
09/18ABBVIE : California Insurance Commissioner Sues AbbVie, Alleging 'Kickbacks' for..
DJ
09/17ABBVIE : Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Stu..
AQ
09/17ABBVIE : to Host Third-Quarter 2018 Earnings Conference Call
PR
More news
News from SeekingAlpha
11:15aEquillium Begins U.S. IPO Effort 
09/19Almirall's tildrakizumab OK'd in Europe for plaque psoriasis 
09/19DIVIDEND SENSEI'S PORTFOLIO UPDATE 5 : Annual Performance Review 
09/18AbbVie used kickbacks to boost Humira sales - CA insurance commissioner 
09/18YOUR CANCER HIGHLIGHT : AbbVie Quietly Aims For A New Best-In-Class Approval In .. 
Financials ($)
Sales 2018 32 862 M
EBIT 2018 14 513 M
Net income 2018 10 305 M
Debt 2018 29 518 M
Yield 2018 4,04%
P/E ratio 2018 13,67
P/E ratio 2019 11,75
EV / Sales 2018 5,09x
EV / Sales 2019 4,74x
Capitalization 138 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 109 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William Joseph Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE-5.88%137 829
MERCK KGAA-2.73%13 180
KYOWA HAKKO KIRIN CO LTD-5.63%10 772
JAZZ PHARMACEUTICALS PLC21.08%9 849
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD49.68%8 332
CONVATEC GROUP10.90%5 877